



ASX ANNOUNCEMENT

Share Purchase Plan Completed

Sydney, 12 July 2018: Actinogen Medical (ASX: ACW or the Company) advises that it has completed its Share Purchase Plan (SPP), raising a total of \$952,500.

The SPP was launched on the 6th of June 2018 and offered to existing eligible investors at \$0.05 a share, which was equal to that of the Institutional Placement price. Eligible shareholders had the opportunity to acquire up to \$15,000 of new fully paid ordinary shares.

Total applications received under the SPP amounted to \$952,500 from 169 shareholders and the Board of Actinogen Medical reserves the right to place any unsubscribed balance of the SPP. The funds are in addition to the \$15m raised via the Institutional Placement, that was corner-stoned by leading specialist US biotech investor *Biotechnology Value Fund L.P.*

A total of 19,050,000 paid ordinary shares will be issued under the SPP on the 13th of July 2018 to participating shareholders, holding statements despatched on that date and the shares will commence trading on the 16th of July 2018.

The funds raised via the Institutional Placement and SPP will be used to drive the development of Xanamem, that includes undertaking additional studies to enhance the data set in the treatment of Alzheimer's disease and other cognitive deficiency associated with other neurological and metabolic diseases.

Chief Executive Officer of Actinogen Medical, Dr Bill Ketelbey commented: "I'd like to thank all our shareholders for their ongoing support of our development of Xanamem. We continue to make good progress with patient enrolment into our XanADu Alzheimer's Phase II clinical trial and the Company remains on track for final patient enrolment before the end of this calendar year and the results from the study in the second quarter of 2019."

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and

is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 β -HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.